These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33442379)

  • 21. Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty.
    Lakshmipathy M; Susvar P; Popet K; Rajagopal R
    Indian J Ophthalmol; 2019 Jul; 67(7):1193-1194. PubMed ID: 31238461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting corneal neovascularization by sustainably releasing anti-VEGF and anti-inflammation drugs from silica-thermogel nanohybrids.
    Lyu N; Zhao Y; Xiang J; Fan X; Huang C; Sun X; Xu J; Xu ZP; Sun J
    Mater Sci Eng C Mater Biol Appl; 2021 Sep; 128():112274. PubMed ID: 34474833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis.
    Papathanassiou M; Theodoropoulou S; Analitis A; Tzonou A; Theodossiadis PG
    Cornea; 2013 Apr; 32(4):435-44. PubMed ID: 22668582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subconjunctival bevacizumab for corneal neovascularization.
    Erdurmus M; Totan Y
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats.
    Hashemian MN; Mahrjerdi HZ; Mazloumi M; Safizadeh MS; Shakiba Y; Rahimi F; Afarideh M; Zare MA; Tafti MF; Sepidan BB; Abtahi MA; Abtahi SH
    J Res Med Sci; 2017; 22():16. PubMed ID: 28458707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
    Yoo AR; Chung SK
    Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
    Park JH; Joo CK; Chung SK
    Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
    Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
    Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
    Roller AB; Amaro MH
    Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX; Bahar I; Levinger E; Rootman D
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical bevacizumab treatment in aniridia.
    Lapid-Gortzak R; Santana NTY; Nieuwendaal CP; Mourits MP; van der Meulen IJE
    Int Ophthalmol; 2018 Aug; 38(4):1741-1746. PubMed ID: 28620705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OUTCOMES OF ANTI-VEGF THERAPY IN CHOROIDAL NEOVASCULARIZATION AFTER MACULAR SURGERY.
    Hua DA; Casella AM; Berrocal MH; Han D; Alshareef RA; Quiroz-Mercado H; Arevalo JF; Chhablani J
    Retin Cases Brief Rep; 2018 Fall; 12(4):359-366. PubMed ID: 28002284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
    Lee HS; Chung SK
    Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
    Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.